Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 128 publications
TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer.
Journal: Journal for immunotherapy of cancer
Published: March 25, 2026
Leveraging real-world evidence to personalize adjuvant therapy in HR+/HER2- early breast cancer.
Journal: JNCI cancer spectrum
Published: July 30, 2025
Current landscape of sequencing ADCs in metastatic breast cancer.
Journal: Therapeutic advances in medical oncology
Published: July 17, 2025
Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.
Journal: The Lancet. Oncology
Published: May 07, 2025
Selection biases in the systematic collection of breast biobank specimens.
Journal: NPJ breast cancer
Published: January 04, 2025
A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast Cancer.
Journal: bioRxiv : the preprint server for biology
Published: December 16, 2024
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 25, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 27, 2024
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 16, 2024
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 05, 2024
Last Updated: 09/26/2026